Symptom clusters of ovarian cancer patients undergoing chemotherapy, and their emotional status and quality of life

Hwang, Kyung‐Hye; Cho, Ok‐Hee; Yoo, Yang‐Sook

doi:10.1016/j.ejon.2015.10.007

Cited by 89 publications

(83 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a cross-sectional Korean study using a modified MSAS in patients with ovarian cancer, there was a high incidence of all symptoms ranging from 60% to 95% compared with 6% to 65% in our study. 8 However, the patients were younger (median age = 49 years) than in our study (median age = 64 years), and age and cultural disparities may influence results. In the study by Friedlander et al 4 using the Symptom Representation Questionnaire, pain (44%), fatigue (37%), and abdominal bloating (32%) were the most commonly reported symptoms at enrollment, however, with lower prevalence compared with the present study.…”

Section: Discussioncontrasting

confidence: 65%

Symptom Experience and Self-rated Physical Functioning in Patients With Ovarian Cancer Receiving Chemotherapy

Vistad

Cvancarova

Astrup

et al. 2018

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

A high symptom burden was reported in this cohort of patients with ovarian cancer mainly treated with palliative intent. Low self-rated physical functioning was strongly associated with high symptom burden for the 6-month period. When chemotherapy is discussed with patients with ovarian cancer with low physical functioning, possible palliation benefits must be weighed against the added risk of long-term distressful symptoms that chemotherapy implies.

show abstract

Section: Discussioncontrasting

confidence: 65%

Symptom Experience and Self-rated Physical Functioning in Patients With Ovarian Cancer Receiving Chemotherapy

Vistad

Cvancarova

Astrup

et al. 2018

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

show abstract

“…For example, depression, which has more recently been shown to commonly co-occur in chemotherapy-induced neuropathy 41 may have provided further post-hoc elucidation of how groups are formed. We used only final TNSc scores to conduct our LCA, and in future describing patients at mid-treatment and observing how OIPN severity group membership may change over time could be helpful for additional insights about the OIPN phenotype.…”

Section: Discussionmentioning

confidence: 99%

Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer

Griffith

Zhu

Johantgen

et al. 2017

Journal of Pain and Symptom Management

View full text Add to dashboard Cite

Context Oxaliplatin-induced peripheral neuropathy (OIPN) is a dose limiting toxicity of oxaliplatin and affects most colorectal cancer (CRC) patients. OIPN is commonly evaluated by patient symptom report, using scales to reflect impairment. They do not discriminate between unique grouping of symptoms and signs, which impedes prompt identification of OIPN. Objective Our study objective was to identify clusters of symptoms and signs that differentiated underlying clinical severity and segregated patients within our population into OIPN subgroups. Methods Chemotherapy naïve CRC patients (N=148) receiving oxaliplatin were administered the Total Neuropathy Score clinical (TNSc©), which includes symptom report (sensory, motor, autonomic) and sensory examination (pin sense, vibration, reflexes). The TNSc© was administered prior to chemotherapy initiation (T0), and following cumulative doses of oxaliplatin 510-520 mg/m2 (T1) and 1020-1040 mg/m2 of oxaliplain (T2). Using mean T2 TNSc© scores, latent class analysis (LCA) grouped patients into OIPN severity cohorts. Results LCA categorized patients into 4 distinct OIPN groups: low symptoms and low signs (N=54); low symptoms and intermediate signs (n=44); low symptoms and high signs (n=21); and high symptoms and high signs (n=29). No differences were noted among OIPN groups on age, sex, chemotherapy regimen, or cumulative oxaliplatin dose. Conclusion We identified OIPN patient groups with distinct symptoms/signs, demonstrating variability of OIPN presentation regardless of cumulative oxaliplatin dose. Over half of the sample had positive findings on OIPN examination despite little or no symptoms. Sensory examination of all patients receiving oxaliplatin is indicated for timely identification of OIPN, which will allow earlier symptom management.

show abstract

“…Jedan set ovih sekvela uključuje fizička oštećenja, kao što su umor, bol, ograničena pokretljivost, limfedem, povećanje telesne mase i dr. Drugi set sekvela uključu-je psihološko-emocionalne probleme koji započinju od trenutka suočavanja sa dijagnozom i različito se manifestuju. Poznato je da fizički odnosno psihološki simptomi mogu dovesti do ograničen-ja u obavljanju uobičajenih dnevnih aktivnosti, profesionalnih i kućnih aktivnosti [9][10][11].…”

Section: Diskusijaunclassified

“…Rezultati sličnih srudija ukazuju da pacijentkinje lečene hemioterapijom imaju izraženije fizičke i psihološke simptome koji negation utiču na aktivnosti dnevnog života i kognitivno funkcionisanje u poređenju sa pacijentkinjama nakon radioterapije odnosno hirurške intervencije [14]. Takođe, negativne posledice hemiterapije manifestuju se fizičkim simptomima kao što su mučnina, povraćanje, diareja i problemi s gutanjem [10]. U našoj studiji svega 9 (18%) ispitanica navelo je problem u vezi sa povraćanjem i diarejom, dok je njih 5 (10%) prijavilo teškoće pri gutanju.…”

Section: Sestrinska Rečunclassified

Nurses assessment of symptoms in cancer patients

Tomić¹,

Malenkovic²,

Nikolić³

2018

Sestrinska reč

View full text Add to dashboard Cite

show abstract

Symptom clusters of ovarian cancer patients undergoing chemotherapy, and their emotional status and quality of life

Cited by 89 publications

References 30 publications

Symptom Experience and Self-rated Physical Functioning in Patients With Ovarian Cancer Receiving Chemotherapy

Symptom Experience and Self-rated Physical Functioning in Patients With Ovarian Cancer Receiving Chemotherapy

Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer

Nurses assessment of symptoms in cancer patients

Contact Info

Product

Resources

About